References
Sun X, Li J, Fan C, Zhang H, Si Y, Fang X et al (2019) Clinical, neuroimaging and prognostic study of 127 cases with infarction of the corpus callosum. Eur J Neurol 26(8):1075–1081
Kasow DL, Destian S, Braun C, Quintas JC, Kagetsu NJ, Johnson CE (2000) Corpus callosum infarcts with atypical clinical and radiologic presentations. AJNR Am J Neuroradiol 21(10):1876–1880
Lehecka M, Dashti R, Hernesniemi J, Niemelä M, Koivisto T, Ronkainen A et al (2008) Microneurosurgical management of aneurysms at the A2 segment of anterior cerebral artery (proximal pericallosal artery) and its frontobasal branches. Surg Neurol 70(3):232–246
Zhang Z, Meng X, Liu W, Liu Z (2019) Clinical features, etiology, and 6-month prognosis of isolated corpus callosum infarction. BioMed Res Int 14(2019):1–9
Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 24(1):35–41
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
GS: acquisition and analysis of data, drafting the manuscript; CM: analysis and interpretation of histological samples; GA, VMA, GS: acquisition and analysis of data, revising the manuscript. AN: analysis and interpretation of MRI imaging; FM: revising the manuscript; analysis of data; study supervision.
Corresponding author
Ethics declarations
Conflicts of interest
S Gelibter, A Genchi, M Callea, S Galantucci, MA Volonté declare no disclosures. N Anzalone is speaker/consultant for Bayer Healthcare and Bracco diagnostic. M Filippi is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The patients provided their written informed consent for this report.
Informed consent
The patient gave her informed consent for this report.
Rights and permissions
About this article
Cite this article
Gelibter, S., Genchi, A., Callea, M. et al. Corpus callosum infarction: radiological and histological findings. J Neurol 267, 3418–3420 (2020). https://doi.org/10.1007/s00415-020-10224-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-020-10224-8